DAWN
Day One Biopharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.22B
P/E Ratio
—
EPS
$-1.04
Beta
-1.75
52W High
$21.53
52W Low
$5.63
50-Day MA
$18.21
200-Day MA
$10.72
Dividend Yield
—
Profit Margin
-67.80%
Forward P/E
—
PEG Ratio
—
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and markets targeted therapies for patients with genetically defined cancers. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $158.18M |
| Gross Profit (TTM) | $140.97M |
| EBITDA | $-124.27M |
| Operating Margin | -51.10% |
| Return on Equity | -22.70% |
| Return on Assets | -14.60% |
| Revenue/Share (TTM) | $1.53 |
| Book Value | $4.28 |
| Price-to-Book | 5.04 |
| Price-to-Sales (TTM) | 14.06 |
| EV/Revenue | 11.29 |
| EV/EBITDA | -7.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83.90% |
| Shares Outstanding | $103.33M |
| Float | $71.35M |
| % Insiders | 16.82% |
| % Institutions | 83.49% |
Analyst Ratings
Consensus ($21.50 target)
8
HoldData last updated: 4/28/2026